 |
 Video: What is a Stock Split?
|
|
|
| Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. According to our ATOS split history records, Atossa Therapeutics has had 3 splits. | |
|
Atossa Therapeutics (ATOS) has 3 splits in our ATOS split history database. The first split for ATOS took place on August 26, 2016. This was a 1 for 15 reverse split, meaning for each 15 shares of ATOS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split. ATOS's second split took place on April 20, 2018. This was a 1 for 12 reverse split, meaning for each 12 shares of ATOS owned pre-split, the shareholder now owned 1 share. For example, a 66.6666666666667 share position pre-split, became a 5.55555555555556 share position following the split. ATOS's third split took place on February 02, 2026. This was a 1 for 15 reverse split, meaning for each 15 shares of ATOS owned pre-split, the shareholder now owned 1 share. For example, a 5.55555555555556 share position pre-split, became a 0.37037037037037 share position following the split.
When a company such as Atossa Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ATOS split history from start to finish, an original position size of 1000 shares would have turned into 0.37037037037037 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Atossa Therapeutics shares, starting with a $10,000 purchase of ATOS, presented on a split-history-adjusted basis factoring in the complete ATOS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/14/2016 |
|
| End date: |
06/12/2026 |
|
| Start price/share: |
$783.00 |
|
| End price/share: |
$2.46 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.69% |
|
| Average Annual Total Return: |
-43.80% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$31.43 |
|
| Years: |
10.00 |
|
|
|
| Date |
Ratio |
| 08/26/2016 | 1 for 15 | | 04/20/2018 | 1 for 12 | | 02/02/2026 | 1 for 15 |
|
|
Free ATOS Email Alerts:
